Upstream Bio (NASDAQ:UPB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Upstream Bio (NASDAQ:UPB) posted its quarterly earnings data on Tuesday. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.05, FiscalAI reports. The firm had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.43 million. Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%.

Upstream Bio Stock Performance

Upstream Bio stock opened at $7.09 on Wednesday. Upstream Bio has a one year low of $5.85 and a one year high of $33.68. The business has a fifty day moving average of $6.83 and a two-hundred day moving average of $10.26. The company has a market cap of $385.84 million, a P/E ratio of -2.44 and a beta of 1.26.

Hedge Funds Weigh In On Upstream Bio

A number of large investors have recently made changes to their positions in UPB. BNP Paribas Financial Markets increased its stake in Upstream Bio by 110.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,527 shares of the company’s stock valued at $123,000 after purchasing an additional 3,430 shares in the last quarter. Bank of America Corp DE grew its holdings in Upstream Bio by 71.2% in the second quarter. Bank of America Corp DE now owns 18,031 shares of the company’s stock valued at $198,000 after purchasing an additional 7,500 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Upstream Bio by 85.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,084 shares of the company’s stock valued at $210,000 after buying an additional 8,788 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Upstream Bio during the 2nd quarter worth $145,000. Finally, Invesco Ltd. boosted its position in shares of Upstream Bio by 6.4% in the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock worth $179,000 after buying an additional 985 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently commented on UPB. Weiss Ratings restated a “sell (e+)” rating on shares of Upstream Bio in a research note on Monday, August 3rd. Truist Financial set a $25.00 price target on shares of Upstream Bio in a research note on Tuesday. Mizuho cut their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. HC Wainwright assumed coverage on shares of Upstream Bio in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, JPMorgan Chase & Co. lowered Upstream Bio from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $35.00 to $8.00 in a report on Friday, June 12th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $29.50.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.